Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma

Giovanni Riva,1* Ivana Lagreca,1* Adriana Mattiolo,2 Daniela Belletti,3 Laura Lignitto,2 Patrizia Barozzi,1 Barbara Ruozzi,3 Daniela Vallerini,4 Chiara Quadrelli,1 Giorgia Corradini,1 Fabio Forghieri,1 Roberto Marasca,1 Franco Nanni,1 Giovanni Tosi,3 Flavio Forni,3 Maria Angela Vandelli,3 Alberto Amadori,2,4 Luigi Chieco-Bianchi,4 Leonardo Potenza,1° Maria Luisa Calabrò,3° and Mario Luppi°

*Contributed equally to this manuscript.
°Contributed equally to this manuscript.

1Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia; Hematology Unit, AOU Policlinico, Modena; 2Immunology and Molecular Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padova; 3Department of Life Sciences, University of Modena and Reggio Emilia, Modena; and 4Department of Surgery, Oncology and Gastroenterology, Oncology and Immunology Section, University of Padova, Italy.

Funding: this work was supported by grants from the Ministero della Salute (Ricerca Finalizzata, CR-2010-2343609, to LP and ML), the Ministero dell’Istruzione, Università e della Ricerca (MIUR, PRIN2009, to ML), the Associazione Italiana per la Ricerca sul Cancro (AIRC, IG 14797-2013, to ML), AIRC and Fondazione Cariverona (grant n. 6599, to ML), and the Associazione Italiana Lotta alle Leucemie, Linfomi e Malform (AIL) - Sezione ‘Luciano Pavarotti’ Modena-ONLUS (to LP and FForghieri). AM and LL were recipients of a fellowship from the Veneto Institute of Oncology.

Correspondence: mario.luppi@unimore.it
doi:10.3324/hematol.2015.126854
Supplementary Information

Sequences of siRNAs against BLIMP1/PRDM1.

In this work, we used the following set of 3 validated anti-BLIMP1/PRDM1 siRNAs (Stealth RNAi™ siRNA, Invitrogen, Life Technologies, Carlsbad, CA, USA), in equal amounts:

5'-GCGACGAAGCCAAUGAAUCAUUAA-3' (ref. PRDM1-HSS101017),

5'-GGCCUUUCAAAUGUCACUUGCAA-3' (ref. PRDM1-HSS101018),

5'-CAGAACGGGAUGAAACAUACUUCU-3' (ref. PRDM1-HSS184611).
Figure S1. Antineoplastic effect of anti-BLIMP1 siRNA/DOTAP lipoplexes in HBL-6 cell line.

(A) Proportions of viable PEL cells and (B) modifications in cellularity over time after treatment with anti-BLIMP1 siRNA/DOTAP lipoplexes, compared with different controls (i.e. untreated cells and cells treated with empty DOTAP liposomes, mock siRNA/DOTAP lipoplexes, or not-vehiculated (free) anti-BLIMP1 siRNAs). Results were obtained as described in Figure 1A and 1B.
Figure S2

Antineoplastic effect of anti-BLIMP1 siRNA/DOTAP lipoplexes in CRO-AP/3 cell line. (A) Proportions of viable PEL cells and (B) modifications in cellularity over time after treatment with anti-BLIMP1 siRNA/DOTAP lipoplexes, compared with different controls (i.e. untreated cells and cells treated with empty DOTAP liposomes, mock siRNA/DOTAP lipoplexes, or not-vehiculated (free) anti-BLIMP1 siRNAs). Results were obtained as described in Figure 1A and 1B.
Figure S3. Caspase-3 activation. Specific activity of Caspase-3 expressed in relative fluorescence units (RFUs) was determined in BCBL-1 cells at 24 and 48 hours, after the treatments indicated above. On the right, recombinant Caspase-3 (rCasp-3; provided with Calbiochem assay kit) was also reported as positive control. In addition, a Caspase-3 inhibitor (DEVD-CHO; provided with the kit) was used as further control, both in cells treated with anti-BLIMP1 siRNA/DOTAP lipoplexes (at 24 and 48 hours) and rCasp-3. Data represent mean values of three independent experiments, performed in triplicate wells for each condition. Error bars represent standard error of the mean.